<DOC>
	<DOCNO>NCT00113958</DOCNO>
	<brief_summary>The purpose study observe effect treatment strategy incorporate cinacalcet HCl management secondary hyperparathyroidism ( HPT ) K/DOQI recommend target subject end stage renal disease ( ESRD ) receive hemodialysis , bio-intact parathyroid hormone , correct serum calcium , serum phosphorus , calcium phosphorus product .</brief_summary>
	<brief_title>Cinacalcet Study Reach Kidney Disease Outcomes Quality Initiative ( K/DOQI ) Levels</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Cinacalcet Hydrochloride</mesh_term>
	<criteria>Men woman must agree use highly effective contraceptive measure throughout study Prescribed hemodialysis least 3 month study day 1 Must receive IV vitamin D sterols 30 day day 1 ( great 2 µg paricalcitol , great 1 µg doxercalciferol , great 0.5 µg calcitriol per dialysis treatment ) The mean 2 biPTH determination obtain central laboratory must great equal 80 pg/mL less equal 160 pg/mL The mean 2 albumin correct serum calcium determination obtain central laboratory must great equal 8.4 mg/dL The mean two Ca x P calculation , base correct serum calcium serum phosphorus determination obtain central laboratory must great 55 mg²/dL Have unstable medical condition , define hospitalize , dialysis vascular access revision , within 30 day day 1 , otherwise unstable judgment investigator Pregnant nursing female Parathyroidectomy 12 week day 1 Received , within 21 day day 1 dose titration phase , therapy medication predominantly metabolize enzyme CYP2D6 narrow therapeutic index ( e.g. , flecainide , vinblastine , thioridazine tricyclic antidepressant ) . The antidepressant amitriptyline permit Received , within 21 day day 1 , therapy medication potent inhibitor ( e.g. , ketoconazole , itraconazole erythromycin ) inducer ( e.g. , rifampin St. John 's Wort ) enzyme CYP3A4 . Phenytoin , phenobarbital carbamazepine also potent inducer enzyme . However , subject stable dose anticonvulsant baseline , evidence seizure activity past 2 month may eligible study Experienced myocardial infarction within 12 week prior day 1 Currently enrol , yet complete least 30 day since end investigational device drug trial , receive investigational agent ( experimental dialysis machine acceptable ) Current gastrointestinal disorder may associate impaired absorption orally administer medication inability swallow tablet Participated study cinacalcet HCl Disorder would interfere understand give informed consent compliance protocol requirement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>End Stage Renal Disease ( ESRD )</keyword>
	<keyword>secondary hyperparathyroidism ( SHPT )</keyword>
	<keyword>hemodialysis</keyword>
	<keyword>biPTH</keyword>
	<keyword>AMG 073 , Amgen</keyword>
</DOC>